[go: up one dir, main page]

HN2011001700A - Compuestos purina - Google Patents

Compuestos purina

Info

Publication number
HN2011001700A
HN2011001700A HN2011001700A HN2011001700A HN2011001700A HN 2011001700 A HN2011001700 A HN 2011001700A HN 2011001700 A HN2011001700 A HN 2011001700A HN 2011001700 A HN2011001700 A HN 2011001700A HN 2011001700 A HN2011001700 A HN 2011001700A
Authority
HN
Honduras
Prior art keywords
purine compounds
purine
compounds
pain
composite
Prior art date
Application number
HN2011001700A
Other languages
English (en)
Inventor
Peter Astles Charles
Guidetti Rossella
Sean Hollinshead Patrick
Wade Tidwell Michael
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011001700A publication Critical patent/HN2011001700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REIERE A UN COMPUESTO DE LA FORMULA I Y COMPOSICIONES FARMACETICAS PARA EL TRATAMIENTO DEL DOLOR
HN2011001700A 2008-12-18 2011-06-17 Compuestos purina HN2011001700A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
HN2011001700A true HN2011001700A (es) 2013-05-06

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001700A HN2011001700A (es) 2008-12-18 2011-06-17 Compuestos purina

Country Status (29)

Country Link
US (1) US8252798B2 (es)
EP (1) EP2379555B1 (es)
JP (1) JP5559812B2 (es)
KR (1) KR101319630B1 (es)
CN (1) CN102256977B (es)
AR (1) AR075104A1 (es)
AU (1) AU2009335997B2 (es)
BR (1) BRPI0923195A2 (es)
CA (1) CA2746740C (es)
CL (1) CL2011001464A1 (es)
CO (1) CO6390101A2 (es)
CR (1) CR20110340A (es)
DO (1) DOP2011000196A (es)
EA (1) EA018386B1 (es)
EC (1) ECSP11011151A (es)
ES (1) ES2536880T3 (es)
HN (1) HN2011001700A (es)
IL (1) IL213167A (es)
MA (1) MA32904B1 (es)
MX (1) MX2011006442A (es)
NZ (1) NZ593088A (es)
PA (1) PA8851501A1 (es)
PE (1) PE20110999A1 (es)
SG (1) SG172253A1 (es)
TN (1) TN2011000291A1 (es)
TW (1) TWI376378B (es)
UA (1) UA104010C2 (es)
WO (1) WO2010080306A1 (es)
ZA (1) ZA201103943B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5647998B2 (ja) * 2009-03-13 2015-01-07 カトリーケ ユニバーシテイト ルーヴェン、ケー．ユー． ルーヴェン アール アンド ディー 免疫抑制剤としてのチアゾロピリミジン調節因子
JP5746698B2 (ja) 2009-08-28 2015-07-08 アリーナ ファーマシューティカルズ， インコーポレイテッド カンナビノイド受容体モジュレーター
RU2012141536A (ru) * 2010-03-17 2014-04-27 Ф. Хоффманн-Ля Рош Аг Имидазопиридины, композиции и способы применения
MX2012011164A (es) * 2010-03-31 2012-11-12 Lilly Co Eli Compuesto de purina usados como agonistas de cb2.
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
WO2012035039A1 (en) 2010-09-15 2012-03-22 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
CA2817785A1 (en) 2010-11-19 2012-05-24 Toby Blench Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
CA2827057C (en) 2011-02-25 2022-06-07 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP3385252B8 (en) 2011-02-25 2022-10-26 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
RU2014113236A (ru) * 2011-09-20 2015-10-27 Ф. Хоффманн-Ля Рош Аг Соединения имидазопиридина, композиции и способы применения
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
KR20150042834A (ko) * 2012-08-16 2015-04-21 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피라졸
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
AU2014261546B2 (en) * 2013-05-02 2018-01-18 F. Hoffmann-La Roche Ag Pyrrolo[2,3-d]pyrimidine derivatives as CB2 receptor agonists
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2018137176A1 (en) * 2017-01-25 2018-08-02 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017184412A1 (en) 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis
EP3558996A4 (en) * 2016-12-21 2020-08-05 Research Triangle Institute, International DIARYLPURINE DERIVATIVES WITH ENHANCED BIOAVAILABILITY
MA48625A (fr) 2017-05-08 2020-03-18 Arena Pharm Inc Composés et méthodes de traitement de la douleur viscérale
WO2024017227A1 (zh) * 2022-07-21 2024-01-25 长春金赛药业有限责任公司 取代的稠环大麻素受体化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
IL87149A (en) 1987-07-20 1994-05-30 Merck & Co Inc 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CN101044143A (zh) * 2004-10-22 2007-09-26 辉瑞产品公司 制备嘌呤化合物的方法
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
SI1989206T1 (sl) * 2006-02-02 2012-11-30 Millennium Pharm Inc Inhibitorji e aktivirajočih enzimov
EP2503890A4 (en) * 2009-11-24 2013-05-15 Glaxosmithkline Llc AZABENZIMIDAZOLE AS A FATTY ACID SYNTHESIS HEMMER
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Also Published As

Publication number Publication date
CA2746740C (en) 2014-01-14
CL2011001464A1 (es) 2012-01-20
JP2012512873A (ja) 2012-06-07
NZ593088A (en) 2012-12-21
UA104010C2 (en) 2013-12-25
EA201170832A1 (ru) 2011-12-30
DOP2011000196A (es) 2011-10-31
AU2009335997A1 (en) 2011-06-23
CN102256977B (zh) 2014-04-16
MX2011006442A (es) 2011-07-19
SG172253A1 (en) 2011-07-28
KR101319630B1 (ko) 2013-10-17
PA8851501A1 (es) 2010-07-27
AR075104A1 (es) 2011-03-09
ECSP11011151A (es) 2011-07-29
MA32904B1 (fr) 2011-12-01
PE20110999A1 (es) 2012-01-16
TWI376378B (en) 2012-11-11
BRPI0923195A2 (pt) 2016-02-16
JP5559812B2 (ja) 2014-07-23
ZA201103943B (en) 2012-11-28
CR20110340A (es) 2011-09-16
IL213167A0 (en) 2011-07-31
ES2536880T3 (es) 2015-05-29
IL213167A (en) 2013-11-28
TN2011000291A1 (en) 2012-12-17
EP2379555B1 (en) 2015-02-25
AU2009335997B2 (en) 2012-05-10
EA018386B1 (ru) 2013-07-30
CA2746740A1 (en) 2010-07-15
US20100160288A1 (en) 2010-06-24
CO6390101A2 (es) 2012-02-29
TW201024296A (en) 2010-07-01
WO2010080306A1 (en) 2010-07-15
KR20110084459A (ko) 2011-07-22
US8252798B2 (en) 2012-08-28
EP2379555A1 (en) 2011-10-26
CN102256977A (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
HN2011001700A (es) Compuestos purina
PA8841901A1 (es) Compuestos orgánicos
ECSP11010778A (es) Amidofenoxiindazoles útiles como inhibidores de c-met
MX357820B (es) Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva.
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CR20120264A (es) Compuestos
PA8740901A1 (es) Compuestos organicos
MX2019003738A (es) Compuestos antivirales.
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
GT200800209A (es) Compuestos organicos
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
UY31065A1 (es) Heterociclos ciclicos
CR20120473A (es) Composiciones y métodos para el diagnóstico y tratamiento de tumores
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
ES2535498T8 (es) Alfa derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento
CO6680689A2 (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CR20120561A (es) Composiciones y métodos para el diagnóstico y tratamiento de tumores
SV2011003784A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
BR112014030992A2 (pt) composições compreendendo calcogenetos e métodos relacionados
ECSP11011131A (es) Derivados de (4-terc-butilpiperazin-2-il)(piperazin-1-il)metanona-n-carboxamida
NI201200196A (es) Agentes terapéuticos 976